For non-US healthcare professionals: Get information about ZOMETA and its product characteristics.
This is an international site for Zometa® (zoledronic acid) and is intended for Health Care Professionals outside the U.S. The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country.
ZOMETA is approved for use in the following countries: Albania, Argentina, Aruba, Australia, Austria, Azerbaijan, Bahrain, Bangladesh, Belarus, Belgium, Bosnia-Herzegovina, Brazil, Bulgaria, Cambodia, Canada, Chile, Colombia, Costa Rica, Croatia, Cuba, Curacao, Cyprus, Czech Republic, Denmark, Dominican Republic, Ecuador, El Salvador, Estonia, Finland, France, Georgia, Germany, Greece, Guatemala, Honduras, Hong Kong, Hungary, Iceland, India, Indonesia, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kazakhstan, Korea, Kuwait, Latvia, Lebanon, Lithuania, Luxembourg, Macedonia, Malaysia, Malta, Mexico, Moldova, New Zealand, Nicaragua, Norway, Oman, Pakistan, Panama, Peru, Philippines, Poland, Portugal, Qatar, Republic Srpska, Romania, Russia, Saudi Arabia, Serbia, Singapore, Slovak Republic, Slovenia, South Africa, Spain, Sri Lanka, Sweden, Switzerland, Syria, Taiwan, Thailand, The Netherlands, Trinidad and Tobago, Turkey, Ukraine, United Arab Emirates, United Kingdom, United States, Uruguay, Uzbekistan, Venezuela.
Below is a list of the countries that host a ZOMETA website based on local label and in local language. They are intended for Healthcare Professional (HCPs) only. Click on any of the links to be redirected to that country-level website.
ZOMETA International Website
This website is intended for Healthcare Professionals (HCPs) outside the U.S. The information on this website is not country specific and may contain information that is outside the approved indication in the country in which you are located. Please contact your local representative for local prescribing information via www.novartisoncology.com/contactus.
IMPORTANT: The information on this website is based on the European Summary of Product Characteristics (EUSmPC)
Skeletal complications can threaten the gains achieved in advanced lung cancer survival1,2
Bone metastases are a major concern for patients with advanced lung cancer3,4
30% to 40% of patients with advanced lung cancer develop bone metastases,* which may lead to bone complications or skeletal-related events (SREs)3†
A clinical trial demonstrated that without treatment with a bone-targeted agent4
48% of patients with lung cancer and bone metastases experienced an SRE within 21 months of follow-up
SRE frequency was approximately every 4 months
*Incidence at autopsy. ‡SREs are generally defined as pathological fractures, spinal cord compression, radiation or surgery to bone, or tumour-induced hypercalcaemia.5
As new treatments extend survival, patients with advanced lung cancer are more likely to experience debilitating SREs1,2
‡Mean time between diagnosis of bone metastasis and first SRE reported in a retrospective US claims database analysis. §Median survival for patients treated with paclitaxel+carboplatin+bevacizumab.
References: 1. Delea T, Langer C, McKiernan J, et al. The cost of treatment of skeletal-related events in patients with bone metastases
from lung cancer. Oncology. 2004;67:390-396. 2. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med. 2006;355:2542-2550. 3. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treatment Rev. 2001;27:165-176. 4. Rosen LS, Gordon D, Tchekmedyian NS, et al; for the Zoledronic Acid Lung Cancer and Other Solid Tumors Group. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer. 2004;100:2613-2621. 5. ZOMETA Summary of Product Characteristics. Novartis Pharma AG. 6. Aapro M, Abrahamsson PA, Body JJ, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol. 2008;19:420-432.
Disclaimer: This is an international website for ZOMETA® (zoledronic acid) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.